Applies to Employer and ACA Marketplace plans.
Not coveredDespite FDA approval for MACE reduction in adults with overweight or obesity and established cardiovascular disease, Wegovy remains classified as an anti-obesity agent. For members whose benefit plans exclude weight loss medications, Wegovy is not covered even when prescribed for cardiovascular risk reduction. Coverage determinations are based on drug classification, not specific indication.
Policy note: This exclusion applies only to commercial and Marketplace (Exchange/ACA) plans. It does NOT apply to Medicare or Medicaid. The document explicitly addresses the MACE/cardiovascular risk reduction indication by name.
Policy effective May 9, 2025 · verified June 4, 2026 · source: Policy 395 · View policy document (PDF)